# Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)

> **NCT06483737** · NA · RECRUITING · sponsor: **General Hospital of Shenyang Military Region** · enrollment: 174 (estimated)

## Conditions studied

- Overt Hepatic Encephalopathy

## Interventions

- **DRUG:** Human albumin infusion at a modified dosage
- **DRUG:** Human albumin infusion at a routine dosage
- **DRUG:** Lactulose
- **DRUG:** Rifaximin
- **DRUG:** Ornithine Aspartate
- **DRUG:** Branched-Chain Amino Acids
- **DRUG:** Arginine

## Key facts

- **NCT ID:** NCT06483737
- **Lead sponsor:** General Hospital of Shenyang Military Region
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-24
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06483737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06483737, "Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06483737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*